stooonks

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

× 🔎 Explain it

---

Orchard Therapeutics PLC

Orchard Therapeutics makes one-time gene therapies that fix the root cause of rare inherited diseases.

Orchard Therapeutics is a small biotech company that makes gene therapies — treatments that try to fix a broken gene at its source rather than just managing symptoms. Its main customers are rare-disease patients and the health systems and insurers that pay for their care. The company's flagship product, Lenmeldy, is a one-time treatment for a devastating inherited condition called metachromatic leukodystrophy, which destroys the nervous system in young children. In the US, Lenmeldy carries a list price of roughly $4.25 million per patient, which is among the highest drug prices in the world.

Think of it as a repair crew that goes into a child's own stem cells, rewrites the faulty instruction, and puts the fixed cells back. The company removes a patient's blood stem cells, uses a modified virus to insert a working copy of the broken gene, and then returns those cells to the patient. Because the fix happens in stem cells, a single treatment can last a lifetime. Orchard also has a treatment for severe immune-system disorders in infants, and several other gene therapies in its pipeline. Revenue is still modest — a few tens of millions of dollars a year — because each treatment is given only once and the patient pool is tiny, but each sale is enormous relative to the number of doses.

The company started in 2015 in London by pulling together several gene-therapy programs, and it grew by buying and licensing technology from academic labs. It went public on NASDAQ in 2018, then struggled as investors grew impatient with slow sales. In early 2025, the Japanese drugmaker Kyowa Kirin agreed to buy Orchard for about $1 billion, taking it private. That deal matters because it gives the company a large parent with deep pockets to pay for expensive clinical trials and to fund expansion of Lenmeldy into more countries, while removing the pressure of quarterly public-market scrutiny. For a curious reader, this is a window into the strange economics of ultra-rare disease medicine: a tiny number of patients, a gigantic price per dose, and a race to reach patients before the disease does irreversible damage.

Saved answer · last researched 11 Oct 2026